EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Improving the Diagnostic Accuracy of Plasma Alzheimer's Disease Biomarkers With Objective and Subjective Cognitive Screening

Maryam Abdolmaleki iD, Leslie S Gaynor, Dandan Liu, Timothy J Hohman, Katherine A Gifford, Henrik Zetterberg, Angela L Jefferson, Corey J Bolton

Annals of Clinical and Translational Neurology · 29.10.2026

DOI: 10.1002/acn3.70565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 29.10.2026. Verfasst von Maryam Abdolmaleki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, Alzheimer's Association, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Blood‐based biomarkers are increasingly used to identify Alzheimer's disease (AD) pathology and may play an important role in early disease screening and participant selection for clinical trials. However, their performance across stages of cognitive impairment remains unclear. This study examined whether plasma biomarkers differ in their ability to predict amyloid pathology by performance on cognitive screening measures.

Methods

Participants were older adults from the community‐based Vanderbilt Memory and Aging Project ( N = 154; mean age = 72 ± 6 years; 37% MCI). Plasma phosphorylated tau (p‐tau) 231 and glial fibrillary acidic protein (GFAP) were measured using Quanterix Simoa technology. Amyloid positivity was defined by cerebrospinal fluid β‐amyloid 42/40 ratio < 0.072. Objective cognitive impairment was defined as ≤ 26 on the Montreal Cognitive Assessment; cognitive complaints were assessed by a single‐item self‐report. Logistic regression and stratified ROC analyses evaluated associations between biomarkers and amyloid status, with area under the ROC curve (AUC) values compared using DeLong's test.

Results

Forty‐seven percent of participants were amyloid positive. Higher plasma p‐tau 231 was associated with increased odds of amyloid positivity (OR = 1.18, p < 0.001; AUC = 0.73). Discriminative accuracy was significantly higher among individuals without subjective cognitive concerns (AUC = 0.85) than among those individuals with concerns (AUC = 0.67; p = 0.02). Plasma GFAP was also associated with amyloid positivity (OR = 1.01, p < 0.001; AUC = 0.75) and showed greater accuracy among participants with objective cognitive impairment (AUC = 0.82) compared to unimpaired individuals (AUC = 0.63; p = 0.03).

Conclusions

Plasma p‐tau 231 and GFAP were associated with amyloid pathology, but their diagnostic accuracy varied by cognitive screening results, highlighting the value of integrating brief cognitive assessments when interpreting blood‐based biomarkers.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid pathologyblood‐based biomarkerscognitive impairmentplasma biomarkers

Autor:innen und Institutionen

  • Vanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Vanderbilt Alzheimer's Disease Research Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • School of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • Division of Geriatric Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

ORCID-Profile: Maryam Abdolmaleki

Förderung

  • NIA NIH HHS
  • Alzheimer's Association
  • National Institute on Aging

Zitieren

APA

Abdolmaleki, M., Gaynor, L. S., Liu, D., Hohman, T. J., Gifford, K. A., Zetterberg, H., Jefferson, A. L., & Bolton, C. J. (2026). Improving the Diagnostic Accuracy of Plasma Alzheimer's Disease Biomarkers With Objective and Subjective Cognitive Screening. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70565

Vancouver

Abdolmaleki M, Gaynor LS, Liu D, Hohman TJ, Gifford KA, Zetterberg H, et al. Improving the Diagnostic Accuracy of Plasma Alzheimer's Disease Biomarkers With Objective and Subjective Cognitive Screening. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70565

BibTeX
@article{Abdolmaleki2026,
  author = {Abdolmaleki, Maryam and Gaynor, Leslie S and Liu, Dandan and Hohman, Timothy J and Gifford, Katherine A and Zetterberg, Henrik and Jefferson, Angela L and Bolton, Corey J},
  title = {Improving the Diagnostic Accuracy of Plasma Alzheimer's Disease Biomarkers With Objective and Subjective Cognitive Screening},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70565}
}
Kostenlos starten →